Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT03058809Phase 1Unknown

Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood

Role: lead

NCT01943500Completed

Collection of Blood Specimens for Circulating Tumor Cell Analysis

Role: lead

All 3 trials loaded